Clinical Trial Update: Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy, safety, and tolerability of RN6G in geographic atrophy associated with age-related macular degeneration was terminated; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• RN6G

Snippet

Sponsor: Pfizer | Conditions: Age-Related Maculopathy | Phase 2 | Status: TERMINATED | Results posted: 2016-03-16